BFM
IONS icon

Boothbay Fund Management’s Ionis Pharmaceuticals IONS Stock Holding History

Boothbay Fund Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$936K Sell
11,808
-64,763
-85% -$4.87M 0.01% 1136
2026
Q1 		$5.75M Buy
76,571
+1,009
+1% +$79.6K 0.07% 281
2025
Q4 		$5.98M Sell
75,562
-87,900
-54% -$6.62M 0.09% 244
2025
Q3 		$10.7M Buy
+163,462
New +$7.98M 0.16% 148

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Boothbay Fund Management's IONS Position: Q2 2026 in Review

Boothbay Fund Management reduced its Ionis Pharmaceuticals (IONS) stake by 85% in Q2 2026, selling an estimated $4.87M and leaving 11,808 shares worth $936K. The position accounts for 0.01% of the portfolio, ranked #1136.

Boothbay Fund Management first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.7M in Q3 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Boothbay Fund Management held 11,808 shares of Ionis Pharmaceuticals worth $936K as of Q2 2026.
  • Boothbay Fund Management sold 64,763 Ionis Pharmaceuticals shares in Q2 2026, an estimated $4.87M.
  • Ionis Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1136 holding.
  • Boothbay Fund Management first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Boothbay Fund Management's Ionis Pharmaceuticals position peaked at $10.7M in Q3 2025.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.